>While Dr. Cox couldn't yet provide sales/revenue estimates for Atryn in the recent conf call, I was wondering if you guys have any ballpark guestimates?<
$25M during the first twelve months after the establishment of reimbursement in the major EU countries is a reasonable projection.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”